Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDAPNASDAQ:MBOTNYSE:MLSSOTCMKTS:VASO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDAPEDAP TMS$1.67-2.6%$1.87$1.26▼$5.46$62.44M0.0198,191 shs60,311 shsMBOTMicrobot Medical$2.50+0.4%$2.53$0.82▼$3.38$90.94M1.141.77 million shs892,475 shsMLSSMilestone Scientific$0.73-4.3%$0.92$0.57▼$1.39$57.05M0.9128,376 shs364,213 shsVASOVaso$0.13-0.1%$0.13$0.11▼$0.32$22.67M1.5527,114 shs142,702 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDAPEDAP TMS-2.62%-1.65%-5.92%-22.33%-67.70%MBOTMicrobot Medical+0.40%+3.73%-11.66%+71.23%+150.00%MLSSMilestone Scientific-4.34%-17.28%-24.97%-26.57%+11.50%VASOVaso-0.08%+1.65%-6.32%+1.42%-53.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDAPEDAP TMS2.9408 of 5 stars3.25.00.00.02.21.70.6MBOTMicrobot Medical2.0012 of 5 stars3.52.00.00.02.70.00.6MLSSMilestone Scientific2.6283 of 5 stars3.55.00.00.00.62.50.0VASOVaso0.4779 of 5 stars0.03.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDAPEDAP TMS 2.33Hold$8.50408.98% UpsideMBOTMicrobot Medical 3.00Buy$9.00260.00% UpsideMLSSMilestone Scientific 3.00Buy$1.2571.94% UpsideVASOVaso 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VASO, MLSS, MBOT, and EDAP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025EDAPEDAP TMSPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral4/10/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/4/2025EDAPEDAP TMSJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $2.003/28/2025EDAPEDAP TMSPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.503/28/2025EDAPEDAP TMSHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDAPEDAP TMS$69.18M0.90N/AN/A$1.18 per share1.42MBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/AMLSSMilestone Scientific$8.61M6.62N/AN/A$0.11 per share6.61VASOVaso$86.77M0.26$0.01 per share12.76$0.16 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDAPEDAP TMS-$20.58M-$0.62N/AN/AN/A-34.45%-51.42%-26.43%8/27/2025 (Estimated)MBOTMicrobot Medical-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)MLSSMilestone Scientific-$6.93M-$0.07N/A∞N/A-52.01%-60.26%-40.23%N/AVASOVaso$950KN/A0.00∞N/A1.20%3.93%1.37%8/12/2025 (Estimated)Latest VASO, MLSS, MBOT, and EDAP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/15/2025Q1 2025EDAPEDAP TMS-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/15/2025Q1 2025VASOVasoN/A-$0.01N/A-$0.01N/A$19.46 million3/31/2025Q4 2024VASOVasoN/A$0.01N/A$0.01N/A$27.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDAPEDAP TMSN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/AVASOVasoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDAPEDAP TMS0.101.741.21MBOTMicrobot MedicalN/A16.1916.19MLSSMilestone ScientificN/A2.851.86VASOVasoN/A1.521.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDAPEDAP TMS62.74%MBOTMicrobot Medical16.30%MLSSMilestone Scientific5.79%VASOVasoN/AInsider OwnershipCompanyInsider OwnershipEDAPEDAP TMS0.23%MBOTMicrobot Medical4.74%MLSSMilestone Scientific24.75%VASOVaso44.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDAPEDAP TMS23037.39 million37.31 millionOptionableMBOTMicrobot Medical2036.38 million34.65 millionOptionableMLSSMilestone Scientific3078.48 million58.61 millionOptionableVASOVaso260175.74 million97.54 millionNot OptionableVASO, MLSS, MBOT, and EDAP HeadlinesRecent News About These CompaniesLevel of physical activity tied to less pain, blood viscosity in SCD: StudyJune 26 at 4:58 PM | sicklecellanemianews.comSCorn in a Cup (Elote en Vaso)June 7, 2025 | msn.comOral inhibitor rilzabrutinib granted FDA orphan drug status for SCDJune 5, 2025 | sicklecellanemianews.comSUS FDA grants orphan drug designation to Sanofi’s rilzabrutinib to treat sickle cell diseaseJune 5, 2025 | pharmabiz.comPSanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell diseaseJune 4, 2025 | medicaldialogues.inMPress Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell diseaseJune 3, 2025 | taiwannews.com.twTSickle cell disease and knee joint pain: Why steriods aren’t always the best optionMay 30, 2025 | punchng.comPVaso Corporation Registered ShsMay 20, 2025 | markets.businessinsider.comVaso Stock Slips Post Q1 Earnings Despite Record Revenue GrowthMay 20, 2025 | zacks.comVaso Corporation Announces Financial Results for First Quarter of 2025May 15, 2025 | globenewswire.comNew tapas and wine bar to open in Nottingham from the team behind MesaMay 6, 2025 | msn.comHe compared him to Justin Bieber, but he got what he deserved in the ringApril 24, 2025 | msn.comThe Zacks Analyst Blog Highlights Apple, Philip Morris International, Sony and VasoApril 21, 2025 | uk.finance.yahoo.comC-Reactive Protein Increases During Menstrual Cycle in Females With Sickle Cell DiseaseApril 18, 2025 | rheumatologyadvisor.comRTop Analyst Reports for Apple, Philip Morris & SonyApril 17, 2025 | finance.yahoo.comShake up your Monday: VASO hosts an electrifying cocktail showdown with top bartendersApril 17, 2025 | myfox28columbus.comMInflammation during menstrual cycle may trigger VOEs: StudyApril 15, 2025 | sicklecellanemianews.comSDangerous 'crises' in sickle cell disease may be amplified by menstrual cycleApril 14, 2025 | msn.comVASO Stock Rises Post Q4 Revenue Growth and Solid Segment GainsApril 7, 2025 | zacks.comVasomedical reports Q4 revenue $27M vs. $21.9M last yearApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVASO, MLSS, MBOT, and EDAP Company DescriptionsEDAP TMS NASDAQ:EDAP$1.67 -0.05 (-2.62%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.66 0.00 (-0.30%) As of 06/27/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.Microbot Medical NASDAQ:MBOT$2.50 +0.01 (+0.40%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.48 -0.02 (-0.60%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Milestone Scientific NYSE:MLSS$0.73 -0.03 (-4.34%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.72 -0.01 (-0.83%) As of 06/27/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.Vaso OTCMKTS:VASO$0.13 0.00 (-0.08%) As of 06/27/2025 03:49 PM EasternVaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
